Psyched Wellness Begins Pre-Clinical Trials Of Amanita Muscaria Mushroom

Psyched Wellness (CSE: PSYC) this morning announced that it has commenced its pre-clinical trials of amanita muscaria mushrooms as of this morning. The milestone was achieved by the company following the first batch of the mushroom extract being shipped to its contract research organization (CRO) partner.

In total, it is said that 108 grams of the extract was sent to the lab to begin the first phase of pre-clinical trials, with the study to be focused on determining the maximum tolerated dose of the extract. In layman terms, the company is looking to determine what dosage of the extract can be used before unacceptable side effects or overt toxicity are encountered with the extract. The announcement comes just one week after the company formally announced that its protocol for extracting the mushroom was a success.

The pre-clinical trials commenced by the company will essentially look to determine the safety, efficacy, and safe dosage levels of the amanita muscaria extract, which will enable the company to ultimately forge ahead with functional mushroom products based on the extract.

“This is a key step, as it is the foundation off which we can apply to the FDA for a New Dietary Ingredient (NDI) and Health Canada for a Natural Health Product Number (NHPN) for our Amanita Muscaria supplement. It will also provide the IP required to focus our team’s attention on studying other more clinical uses of Amanita Muscaria for mental and physical health issues.”

Jeff Stevens, CEO of Psyched Wellness

Jeff Stevens, the CEO of Psyched Wellness, recently joined us on our latest video series, SmallCapSteve LIVE!, wherein he laid out the value proposition for the amanita muscaria mushroom, and where the company intends to focus in the future. You can catch this discussion in the video below.

Psyched Wellness last traded at $0.275 on the CSE.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Psyched Wellness Completes Extraction Protocol For First Mushroom Products

Psyched Wellness (CSE: PSYC) has completed a number of milestones with regards to getting its...

Thursday, December 10, 2020, 07:45:56 AM

Psyched Wellness Completes Maximum Tolerated Dosage Study For Amanita Muscaria Extract AME-1

Psyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing...

Tuesday, March 2, 2021, 07:24:03 AM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM

Psyched Wellness Completes 14 Day Oral Toxicity Preclinical Study For Proprietary Extract

Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity...

Tuesday, July 6, 2021, 08:58:10 AM

Psyched Wellness Announces Study On Muscimol Antioxidant and Anti-Inflammatory Properties

Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita...

Wednesday, January 6, 2021, 07:48:08 AM